Table 2 Subgroup analysis based on various covariates

All

0.80(0.77–0.83)

0.79(0.73–0.84)

15.18(10.07–22.87)

3.85(2.94–5.04)

0.25(0.21–0.30)

0.83(0.79–0.86

I²(%)

36.8%

76.1%

99.9%

63.4%

46.3%

Measurement units

μg/L(3)

0.82(0.76–0.86)

0.78(0.73–0.82)

20.46(7.91–52.90)

4.26(2.58–7.03)

0.23(0.14–0.35)

0.88 (0.80–0.94)

I²(%)

53.8%

68.3%

74.3%

70.9%

56.8%

Non-μg/L(5)

0.79(0.75–0.82)

0.79(0.70–0.85)

13.46(8.35–21.69)

3.66(2.60–5.16)

0.27(0.22–0.33)

0.80 (0.76–0.83)

I²(%)

30.8%

82.4%

98.8%

68.6%

38.51%

Pathological types

BTCC(5)

0.79(0.73–0.84)

0.80(0.73–0.85)

14.62(8.41–25.41)

3.87(2.85–5.23)

0.26(0.20–0.36)

0.86(0.83–0.89)

I²(%)

53.8%

39.4%

99.7%

0.0%

51.5%

BTCC&SCC(3)

0.82(0.77–0.86)

0.77(0.72–0.81)

15.09(6.09–37.42)

3.66(1.88–7.14)

0.25(0.18–0.33)

0.89(0.86–0.92)

I²(%)

0.0%

90.2%

82.6%

91.0%

35.4%

Study objects

Primary tumor(7)

0.79(0.76–0.82)

0.78(0.72–0.83)

13.18(9.19–18.91)

3.58(2.78–4.61)

0.27(0.23–0.32)

0.80(0.77–0.84)

I²(%)

0.0%

74.4%

97.8%

55.2%

7.3%

Residual tumor(1)

0.91(0.71–0.98)

0.88(0.70–0.93)

73.50(22.60–239.04)

0.73(0.55–0.89)

0.93(0.72–0.98)

0.90(0.83–0.92)

Assay methods

ELISA(3)

0.82(0.77–0.86)

0.77(0.72–0.81)

15.09(6.09–37.42)

3.66(1.88–7.14)

0.25(0.18–0.33)

0.89(0.86–0.92)

I²(%)

0.0%

90.2%

82.6%

91.0%

35.4%

Non-ELISA(5)

0.79(0.73–0.84)

0.80(0.73–0.85)

14.62(8.41–25.41)

3.87(2.85–5.23)

0.26(0.20–0.36)

0.86(0.83–0.89)

I²(%)

53.8%

39.4%

99.7%

0.0%

51.5%

NMIBC > 50%

Yes(4)

0.79(0.70–0.85)

0.83(0.76–0.87)

17.32(8.51–35.28)

4.50(3.11–6.52)

0.26(0.17–0.39)

0.87(0.84–0.90)

I²(%)

62.6%

0.0%

99.2%

0.0%

63.8%

No evidence(4)

0.81(0.77–0.85)

0.77(0.67–0.84)

14.23(8.02–25.23)

3.48(2.39–5.05)

0.24(0.19–0.31)

0.83(0.80–0.86)

I²(%)

0.00%

86.09%

99.9%

75.8%

16.89%